Physical Cold Atmospheric Plasma for the Treatment of Cervical Intraepithelial Neoplasia

NCT ID: NCT03218436

Last Updated: 2024-07-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

63 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-09-01

Study Completion Date

2022-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cervical intraepithelial neoplasia will be treated with physical low temperature plasma in the plasma cohort compared to watchful waiting in the control cohort.

Primary endpoint after 3-6 months: Pathological remission.

Secondary endpoint: HPV remission.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study was completed with Less recruitment as it was planned due to overwhelming study success. The study was published in August 2023. A link has been added to the Reference section.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cervical Intraepithelial Neoplasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CAP cohort

Cold Atmospheric plasma intervention

Group Type ACTIVE_COMPARATOR

CAP treatment

Intervention Type PROCEDURE

Treatment with low-temperature argon plasma during colposcopic examination. No general anesthesia required.

Control cohort

no intervention

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CAP treatment

Treatment with low-temperature argon plasma during colposcopic examination. No general anesthesia required.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed CIN I / II
* Reliable assessment of the radius of the portio and marginal borders of the lesions
* Written consent for treatment with low temperature plasma after reconnaissance


* Histologically confirmed CIN I / II
* Reliable assessment of the radius of the portio and marginal borders of the lesions
* Patients who want a waiting procedure and a control examination after 3-6 months

Exclusion Criteria

* Histologically confirmed CIN III
* Not fully visible transformation zone
* An indication of invasive disease
* Expected lack of compliance of the patient or incapacity of the patient to understand the meaning and purpose of the clinical trial
* Severe cardio-vascular disease
* Lack of patient consent
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital Tuebingen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Melanie Henes, Dr.

Role: PRINCIPAL_INVESTIGATOR

Department for Women's Health

Martin Weiss, Dr.

Role: PRINCIPAL_INVESTIGATOR

Department for Women's Health

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department for Women's Health

Tübingen, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Weiss M, Arnholdt M, Hissnauer A, Fischer I, Schonfisch B, Andress J, Gerstner S, Dannehl D, Bosmuller H, Staebler A, Brucker SY, Henes M. Tissue-preserving treatment with non-invasive physical plasma of cervical intraepithelial neoplasia-a prospective controlled clinical trial. Front Med (Lausanne). 2023 Aug 15;10:1242732. doi: 10.3389/fmed.2023.1242732. eCollection 2023.

Reference Type DERIVED
PMID: 37654659 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

https://pubmed.ncbi.nlm.nih.gov/37654659/

doi: 10.3389/fmed.2023.1242732

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CAP CIN

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.